Artivion is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Our purpose is to develop simple, elegant solutions that address cardiac and vascular surgeons’ most difficult challenges in treating patients with diseases of the aorta and deliver breakthrough technologies of unsurpassed quality that have far-reaching impact. Our decades of expertise in treating aortic diseases—coupled with our recent acquisitions and partnerships—have empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts, surgical sealants, prosthetic heart valves, and aortic stents and stent-grafts.
Artivion has over 1,600 employees worldwide with sales representation in over 100 countries. The Company has manufacturing facilities located in Atlanta, Georgia, Austin, Texas, Hechingen, Germany, and Herzliya, Israel. Additionally, it has sales and distribution offices in various countries throughout Europe, Asia, and South America.
CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development.
Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards.
CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected.
We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population.
CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category.
CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.
XtalPi (HKEX: 2228) is the AI for Science research infrastructure platform powered by large-scale autonomated labs for pharmaceuticals, advanced materials, new energy, and chemicals.
We build AI models that predict molecular properties, design experiments autonomously, and learn from every result in real time. Robotic workstations in our labs run thousands of parallel experiments across chemistry and biology, generating the high-quality data that trains the next generation of models — closing the loop between computation and physical reality. From early-stage drug discovery to materials formulation, this cycle shrinks what used to take years into months, and what required hundreds of trial-and-error iterations into targeted, data-driven decisions.
We are building the foundation to connect AI reasoning with physical experimentation across every step of the scientific method.
We believe this new research infrastructure will enable scientists to turn ambitious ideas into tangible solutions for human health, sustainable materials, and the global energy transition at a pace and scale never experienced before.